Health Care [ 6/12 ] | Biotechnology [ 32/73 ]
NASDAQ | Common Stock
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy.
The company was founded in 2018 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 25 | -0.92 Decreased by -46.03% | -0.72 Decreased by -27.78% |
| Feb 24, 25 | -0.68 Increased by +16.05% | -0.81 Increased by +16.05% |
| Nov 8, 24 | -0.66 Increased by +32.65% | -0.87 Increased by +24.14% |
| Aug 8, 24 | -0.87 Decreased by -6.10% | -0.72 Decreased by -20.83% |
| May 14, 24 | -0.63 Increased by +8.70% | -0.74 Increased by +14.86% |
| Mar 6, 24 | -0.81 Decreased by -237.50% | -1.01 Increased by +19.80% |
| Nov 8, 23 | -0.98 Decreased by -24.05% | -0.88 Decreased by -11.36% |
| Aug 8, 23 | -0.82 Increased by +33.33% | -0.81 Decreased by -1.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -30.20 M Decreased by -67.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -22.24 M Decreased by -14.09% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.38 M Increased by +8.18% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -28.34 M Decreased by -45.14% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -18.02 M Decreased by -10.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.66 M Increased by +N/A% | -19.50 M Decreased by -30.52% | Decreased by -1.17 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -23.29 M Decreased by -25.17% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -19.52 M Decreased by -12.75% | Decreased by N/A% Decreased by N/A% |